论文部分内容阅读
血中载脂蛋白A I(ApoA I)浓度与动脉粥样硬化的发生率呈负相关.ApoA I是体内抗动脉粥样硬化的因素,是预测冠心病发病危险的指标之一.在意大利乡村的一些居民体内发现了ApoA I Milano,这些人高密度脂蛋白胆固醇水平极低,但却很少发生心血管病.从而在ApoA I Milano对动脉粥样硬化的临床治疗方面进行了一系列研究.近期已研制出此类相关实验性药物:ECT-216,可以清除动脉粥样硬化斑块.这是第一次一种药物能显著地逆转动脉粥样硬化.本文就ApoA I与动脉粥样硬化治疗新进展综述如下.
ApoA I was negatively correlated with the incidence of atherosclerosis.ApoA I is an in vivo anti-atherosclerotic factor and one of the predictors of the risk of coronary heart disease.ApoA I in rural Italy Some residents found ApoA I Milano, who had very low levels of HDL cholesterol but few cardiovascular disease, and conducted a series of studies in ApoA I Milano’s clinical approach to atherosclerosis. Has developed such related experimental drugs: ECT-216, can remove atherosclerotic plaque.This is the first time a drug can significantly reverse atherosclerosis.In this paper, ApoA I and atherosclerosis treatment The new progress is summarized as follows.